Indications
Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Composition
- Active substance
- patisiran sodium
- International name (INN)
- patisiran
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Onpattro
- Active substance
- patisiran sodium
- ATC code
- N07
- Group
- Nervous system
- Therapeutic area
- Amyloidosis, Familial
- Marketing authorisation holder
- Alnylam Netherlands B.V.
- Status
- Authorised